US2012270249A1PendingUtilityA1

Medium for the specific detection of resistant microorganisms

63
Assignee: ORENGA SYLVAINPriority: Feb 10, 2005Filed: Jun 29, 2012Published: Oct 25, 2012
Est. expiryFeb 10, 2025(expired)· nominal 20-yr term from priority
C12Q 1/045C12Q 1/527C12Q 1/04C12Q 1/37C12Q 1/34C12Q 1/14C12Q 1/10
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for distinguishing among a first group of microorganisms, belonging to a first taxon of bacteria that is vancomycin resistant; a second group of microorganisms, belonging to a second taxon of vancomycin resistant bacteria that is different than said first taxon; and a third group of microorganisms that is not resistant or has a natural resistance to vancomycin.

Claims

exact text as granted — not AI-modified
1 . A method for distinguishing among at least three groups of microorganisms that may be present in a biological sample, the at least three groups comprising:
 a first group of microorganisms, belonging to a first taxon of bacteria that is vancomycin resistant;   a second group of microorganisms, belonging to a second taxon of vancomycin resistant bacteria that is different than said first taxon; and   a third group of microorganisms that is not resistant or has a natural resistance to vancomycin, the method comprising:   inoculating a culture medium with the biological sample, the culture medium comprising:
 a first substrate for detecting a first enzymatic or metabolic activity of said first group of microorganisms; 
 a marker for differentiating the first group of microorganisms and the second group of microorganisms, said marker being a substrate for detecting an enzymatic or metabolic activity of said second group of microorganisms; and 
 an antimicrobial that is active on the third group of microorganisms, and 
   distinguishing among any members of the three groups of microorganisms that are present on the culture medium to determine of which group of microorganisms they are members on the basis of their interactions with the first substrate, the markers, and the antimicrobial.   
     
     
         2 . The method of  claim 1 , wherein:
 the first group of microorganisms is enterococcal bacteria that have an acquired resistance to vancomycin;   the second group of microorganisms is enterococcal bacteria that have a natural resistance to vancomycin; and   the third group of microorganisms is enterococcal bacteria that is not resistant to vancomycin.   
     
     
         3 . The method of  claim 1 , wherein:
 the first group of vancomycin-resistant microorganisms comprises  Enterococcus faecalis  and  Enterococcus faecium;      the second group of vancomycin-resistant microorganisms comprises  Enterococcus casseliflavus  and  Enterococcus gallinarum ; and   the third group of microorganisms is not resistant to vancomycin.   
     
     
         4 . The method of  claim 1 , wherein:
 the first group of vancomycin-resistant microorganisms comprises  Enterococcus faecium;      the second group of vancomycin-resistant microorganisms comprises  Enterococcus faecalis ; and   the third group of microorganisms is enterococcal bacteria that is not resistant to vancomycin or that have a natural resistance to vancomycin.   
     
     
         5 . The method of  claim 1 , wherein:
 the first group of vancomycin-resistant microorganisms comprises  Enterococcus faecalis  and  Enterococcus faecium;      the second group of vancomycin-resistant microorganisms comprises  Staphylococcus aureus  that is intermediary resistant or resistant to vancomycin; and   the third group of microorganisms is not resistant to vancomycin.   
     
     
         6 . The method of  claim 1 , wherein:
 the first substrate is a substrate for detecting a beta-glucosidase activity,   the marker is a second substrate for detecting methyl-alpha-glucoside metabolism in the presence of a colored indicator, and   the antimicrobial is vancomycin.   
     
     
         7 . The method of  claim 1 , wherein:
 the first substrate is a substrate for detecting alpha-glucoside metabolism;   the marker is a second substrate for detecting a second activity different than alpha-glucoside metabolism; and   the antimicrobial is vancomycin.   
     
     
         8 . The method of  claim 7 , wherein the second substrate detects beta-glucosidase or beta-galactosidase activity. 
     
     
         9 . The method of  claim 7 , wherein:
 the first substrate is methyl-α-glucoside, and   the second substrate is 5-bromo-4-chloro-3-indolyl-β-D-glucoside or 6-chloro-3-indolyl-β-D-glucoside.   
     
     
         10 . The method of  claim 7 , wherein:
 the first substrate is 5-bromo-4-chloro-3-indolyl-N-methyl-α-D-glucoside or 5-bromo-4-chloro-3-indolyl-α-D-glucoside, and   the second substrate is 6-chloro-3-indolyl-β-D-glucoside, alizarine-β-D-galactoside, 5-bromo-6-chloro-3-indolyl-β-D-glucoside, 5-bromo-6-chloro-3-indolyl-β-D-galactoside or 6-chloro-3-indolyl-β-D-galactoside.   
     
     
         11 . The method of  claim 7 , wherein:
 the first substrate is 5-bromo-4-chloro-3-indolyl-N-methyl-α-D-glucoside or 5-bromo-4-chloro-3-indolyl-α-D-glucoside, and   the second substrate is 6-chloro-3-indolyl-β-D-glucoside or 5-bromo-6-chloro-3-indolyl-β-D-glucoside.   
     
     
         12 . The method of  claim 1 , wherein:
 the first group of microorganisms is enterococcal bacteria that have an acquired resistance to vancomycin;   the second group of microorganisms is enterococcal bacteria that have a natural resistance to vancomycin;   the third group of microorganisms is enterococcal bacteria that is not resistant to vancomycin, and   wherein:
 the first substrate is a substrate for detecting a beta-glucosidase activity, 
 the marker is a second substrate for detecting methyl-alpha-glucoside metabolism in the presence of a colored indicator, and 
 the antimicrobial is vancomycin. 
   
     
     
         13 . The method of  claim 1 , wherein:
 the first group of vancomycin-resistant microorganisms comprises  Enterococcus faecalis  and  Enterococcus faecium;      the second group of vancomycin-resistant microorganisms comprises  Enterococcus casseliflavus  and  Enterococcus gallinarum;      the third group of microorganisms is not resistant to vancomycin, and wherein:
 the first substrate is a substrate for detecting alpha-glucoside metabolism; 
 the marker is a second substrate for detecting a second activity different than alpha-glucoside metabolism; and 
 the antimicrobial is vancomycin. 
   
     
     
         14 . The method of  claim 1 , wherein:
 the first group of vancomycin-resistant microorganisms comprises  Enterococcus faecium;      the second group of vancomycin-resistant microorganisms comprises  Enterococcus faecalis;      the third group of microorganisms is enterococcal bacteria that is not resistant to vancomycin or that have a natural resistance to vancomycin, and   wherein:
 the first substrate is a substrate for detecting alpha-glucoside metabolism; 
 the marker is a second substrate for detecting a second activity different than alpha-glucoside metabolism; and 
 the antimicrobial is vancomycin. 
   
     
     
         15 . The method of  claim 1 , wherein:
 the first group of vancomycin-resistant microorganisms comprises  Enterococcus faecalis  and  Enterococcus faecium;      the second group of vancomycin-resistant microorganisms comprises  Staphylococcus aureus  that is intermediary resistant or resistant to vancomycin;   the third group of microorganisms are not resistant to vancomycin; and   wherein:
 the first substrate is a substrate for detecting alpha-glucoside metabolism; 
 the marker is a second substrate for detecting a second activity different than alpha-glucoside metabolism; and 
 the antimicrobial is vancomycin. 
   
     
     
         16 . The method of  claim 1 , wherein:
 the first group of vancomycin-resistant microorganisms comprises  Enterococcus faecalis  and  Enterococcus faecium;      the second group of vancomycin-resistant microorganisms comprises  Enterococcus casseliflavus  and  Enterococcus gallinarum;      the third group of microorganisms is not resistant to vancomycin, and   wherein:
 the first substrate is a substrate for detecting alpha-glucoside metabolism; 
 the marker is a second substrate for detecting beta-glucosidase or beta-galactosidase activity; and 
 the antimicrobial is vancomycin. 
   
     
     
         17 . The method of  claim 1 , wherein:
 the first group of vancomycin-resistant microorganisms comprises  Enterococcus faecium;      the second group of vancomycin-resistant microorganisms comprises  Enterococcus faecalis;      the third group of microorganisms is enterococcal bacteria that is not resistant to vancomycin or that have a natural resistance to vancomycin, and   wherein:
 the first substrate is 5-bromo-4-chloro-3-indolyl-N-methyl-a-D-glucoside or 5-bromo-4-chloro-3-indolyl-a-D-glucoside; 
 the marker is 6-chloro-3-indolyl-β-D-glucoside, alizarine-β-D-galactoside, 5-bromo-6-chloro-3-indolyl-β-D-glucoside, 5-bromo-6-chloro-3-indolyl-β-D-galactoside or 6-chloro-3-indolyl-β-D-galactoside; and 
 the antimicrobial is vancomycin. 
   
     
     
         18 . The method of  claim 1 , wherein:
 the first group of vancomycin-resistant microorganisms comprises  Enterococcus faecalis  and  Enterococcus faecium;      the second group of vancomycin-resistant microorganisms comprises  Staphylococcus aureus  that is intermediary resistant or resistant to vancomycin;   the third group of microorganisms is not resistant to vancomycin, and   wherein:
 the first substrate is 5-bromo-4-chloro-3-indolyl-N-methyl-a-D-glucoside or 5-bromo-4-chloro-3-indolyl-a-D-glucoside; 
 the marker is 6-chloro-3-indolyl-β-D-glucoside or 5-bromo-6-chloro-3-indolyl-β-D-glucoside; and 
 the antimicrobial is vancomycin.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.